Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 9/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.49 |
| ▸ | HTR1A | P08908 | 2/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.49 |
| ▸ | PRMT5 | O14744 | 3/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17583880 | 0.75 | PRMT5 (0.47) | KDM1ASLC6A4HTR1ASLC6A2SLC6A3 | |
| SCHEMBL30041677 | 0.74 | KDM1A (0.52) | KDM1ASLC6A4HTR1ASLC6A2SLC6A3 | |
| SCHEMBL23674986 | 0.74 | KDM1A (0.57) | KDM1ASLC6A4HTR1ASLC6A2SLC6A3 | |
| SCHEMBL30207838 | 0.70 | MAOA (0.40) | HTR1AHTR2AHTR2C | |
| SCHEMBL13139207 | 0.68 | MAOA (0.68) | HTR2AHTR2C | |
| SCHEMBL23674423 | 0.68 | KDM1A (0.49) | KDM1ASLC6A4HTR1ASLC6A2SLC6A3 | |
| SCHEMBL3041831 | 0.68 | MAOA (0.68) | HTR2AHTR2C | |
| SCHEMBL19667285 | 0.68 | KDM1A (0.49) | KDM1ASLC6A4HTR1ASLC6A2SLC6A3 | |
| SCHEMBL6376366 | 0.67 | PRMT5 (0.51) | PRMT5 | |
| SCHEMBL30112171 | 0.67 | KDM1A (0.48) | KDM1ASLC6A4HTR1ASLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10220037-B2 | Substituted carbonucleoside derivatives useful as anticancer agents | PFIZER INC. (US) | 2019-03-05 | — | — | US | disclosed |
| US-20170348313-A1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. (US) | 2017-12-07 | — | — | US | disclosed |
| US-20170348313-A1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. (US) | 2017-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170348313-A1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | DUT, NCL, TYMP | KDM1A 3216/4885SLC6A4 4329/4885HTR1A 4648/4885 |
| US-10220037-B2 | Substituted carbonucleoside derivatives useful as anticancer agents | DUT, NCL, TYMP | KDM1A 3216/4885SLC6A4 4329/4885HTR1A 4648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.